HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nikolas Herold Selected Research

SAM Domain and HD Domain-Containing Protein 1

1/2021Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.
10/2018Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nikolas Herold Research Topics

Disease

9Neoplasms (Cancer)
01/2024 - 01/2017
6Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2024 - 01/2017
5Infections
01/2019 - 12/2014
4Neuroblastoma
01/2022 - 10/2017
3Osteosarcoma (Osteogenic Sarcoma)
02/2024 - 09/2020
2Hematologic Neoplasms (Hematological Malignancy)
05/2024 - 02/2017
2Sarcoma (Soft Tissue Sarcoma)
02/2024 - 01/2023
2Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2024 - 03/2022
1Cardiotoxicity
01/2023
1Crohn Disease (Crohn's Disease)
01/2023
1Bites and Stings (Sting)
02/2022
1Lymphoma (Lymphomas)
02/2022
1Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell)
01/2022
1Hodgkin Disease (Hodgkin's Disease)
01/2021
1Disease Progression
01/2017

Drug/Important Bio-Agent (IBA)

9Proteins (Proteins, Gene)FDA Link
02/2024 - 01/2016
8Cytarabine (Cytosar-U)FDA LinkGeneric
01/2024 - 01/2017
4triphosphoric acid (triphosphate)IBA
01/2024 - 01/2017
3AntimetabolitesIBA
07/2018 - 01/2017
3NucleosidesIBA
07/2018 - 01/2017
2CTPaseIBA
01/2024 - 01/2017
2RNA (Ribonucleic Acid)IBA
01/2023 - 01/2016
2Biomarkers (Surrogate Marker)IBA
02/2022 - 01/2022
2Cytostatic AgentsIBA
01/2021 - 02/2017
2SAM Domain and HD Domain-Containing Protein 1IBA
01/2021 - 10/2018
2DeoxycytidineIBA
01/2020 - 02/2017
13- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA
02/2024
1Histidine (L-Histidine)FDA Link
01/2024
1Aspartic Acid (Aspartate)FDA Link
01/2024
1Phosphotransferases (Kinase)IBA
11/2023
1AnthracyclinesIBA
01/2023
1InterferonsIBA
02/2022
1Messenger RNA (mRNA)IBA
02/2022
1RadiopharmaceuticalsIBA
01/2022
1Mitogen-Activated Protein KinasesIBA
01/2022
1Doxorubicin (Adriamycin)FDA LinkGeneric
04/2021
1vesicular stomatitis virus G proteinIBA
01/2019
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
01/2019
1Protein Isoforms (Isoforms)IBA
01/2019
1Adenosine Triphosphatases (ATPase)IBA
01/2019
1Complementary DNA (cDNA)IBA
10/2017
1Arabinofuranosylcytosine TriphosphateIBA
01/2017
1DNA (Deoxyribonucleic Acid)IBA
01/2016
1Antiviral Agents (Antivirals)IBA
01/2016
1Interferon Type IIBA
01/2016
1Capsid Proteins (Capsid Protein)IBA
01/2016
1CytokinesIBA
01/2016
1Dynamin IIIBA
12/2014

Therapy/Procedure

10Therapeutics
11/2023 - 01/2016
5Drug Therapy (Chemotherapy)
03/2022 - 01/2017
2Radiotherapy
01/2022 - 01/2021
2Immunotherapy
01/2021 - 07/2018
1Stem Cell Transplantation
03/2022
1Consolidation Chemotherapy
10/2018
1Combination Drug Therapy (Combination Chemotherapy)
07/2018
1Adjuvant Radiotherapy
10/2017